AU2003291885A1 - Compounds and methods for the treatment or prevention of flavivirus infections - Google Patents
Compounds and methods for the treatment or prevention of flavivirus infectionsInfo
- Publication number
- AU2003291885A1 AU2003291885A1 AU2003291885A AU2003291885A AU2003291885A1 AU 2003291885 A1 AU2003291885 A1 AU 2003291885A1 AU 2003291885 A AU2003291885 A AU 2003291885A AU 2003291885 A AU2003291885 A AU 2003291885A AU 2003291885 A1 AU2003291885 A1 AU 2003291885A1
- Authority
- AU
- Australia
- Prior art keywords
- prevention
- compounds
- treatment
- methods
- flavivirus infections
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D333/40—Thiophene-2-carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43196402P | 2002-12-10 | 2002-12-10 | |
| US60/431,964 | 2002-12-10 | ||
| PCT/CA2003/001912 WO2004052885A1 (en) | 2002-12-10 | 2003-12-09 | Compounds and methods for the treatment or prevention of flavivirus infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2003291885A1 true AU2003291885A1 (en) | 2004-06-30 |
Family
ID=42828817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003291885A Abandoned AU2003291885A1 (en) | 2002-12-10 | 2003-12-09 | Compounds and methods for the treatment or prevention of flavivirus infections |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1569929B9 (https=) |
| JP (1) | JP4926403B2 (https=) |
| AT (1) | ATE466856T1 (https=) |
| AU (1) | AU2003291885A1 (https=) |
| BR (1) | BR0316771A (https=) |
| CA (1) | CA2508990C (https=) |
| DK (1) | DK1569929T3 (https=) |
| MX (1) | MXPA05006196A (https=) |
| NZ (1) | NZ540799A (https=) |
| WO (1) | WO2004052885A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004061746A1 (de) * | 2004-12-22 | 2006-07-06 | Bayer Healthcare Ag | Alkinyl-substituierte Thiophene |
| BRPI0610283A2 (pt) | 2005-05-13 | 2010-10-19 | Virochem Pharma Inc | composto, uso do mesmo na preparação de um medicamento para o tratamento ou prevenção de uma infecção por vìrus de hepatite c, composição farmacêutica e combinação farmacêutica |
| PE20070814A1 (es) * | 2005-12-22 | 2007-08-16 | Smithkline Beecham Corp | Compuestos derivados de 2-carboxitiofeno como inhibidores de la polimerasa del virus de la hepatitis c (hcv) |
| WO2008017688A1 (en) * | 2006-08-11 | 2008-02-14 | Smithkline Beecham Corporation | 2-carboxy thiophene derivatives as anti-viral agents |
| WO2008043791A2 (en) * | 2006-10-13 | 2008-04-17 | Smithkline Beecham Corporation | Thiophene derivatives for treating hepatitis c |
| CA2670260A1 (en) * | 2006-11-15 | 2008-05-22 | Virochem Pharma Inc. | Thiophene analogues for the treatment or prevention of flavivirus infections |
| ES2381410T3 (es) | 2007-05-04 | 2012-05-28 | Vertex Pharmceuticals Incorporated | Terapia de combinación paa el tratamiento de infecciones por VHC |
| GB0712393D0 (en) * | 2007-06-26 | 2007-08-01 | Smithkline Beecham Corp | Compounds |
| US9962368B2 (en) | 2009-01-09 | 2018-05-08 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| US9095572B2 (en) | 2009-01-09 | 2015-08-04 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| US9162980B2 (en) | 2009-01-09 | 2015-10-20 | Board Of Regents Of The University Of Texas System | Anti-depression compounds |
| US8362277B2 (en) | 2009-01-09 | 2013-01-29 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| EP2385829B1 (en) | 2009-01-09 | 2018-08-01 | Board of Regents of the University of Texas System | Pro-neurogenic compounds |
| WO2011011303A1 (en) | 2009-07-21 | 2011-01-27 | Gilead Sciences, Inc. | Inhibitors of flaviviridae viruses |
| ES2559437T3 (es) * | 2009-09-09 | 2016-02-12 | Gilead Sciences, Inc. | Inhibidores de virus de la familia Flaviviridae |
| JP2013512247A (ja) * | 2009-11-25 | 2013-04-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス感染症の治療または予防のための5−アルキニル−チオフェン−2−カルボン酸誘導体およびそれらの使用 |
| AP3576A (en) | 2010-01-15 | 2016-02-08 | Gilead Sciences Inc | Inhibitors of flaviviridae viruses |
| CA2785563C (en) | 2010-01-15 | 2019-05-14 | Gilead Sciences, Inc. | Inhibitors of flaviviridae viruses |
| WO2012006070A1 (en) * | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
| AU2011292040A1 (en) * | 2010-08-17 | 2013-03-07 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of Flaviviridae viral infections |
| EP2651906A4 (en) | 2010-12-17 | 2014-06-25 | Cocrystal Discovery Inc | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE |
| AU2012280959B2 (en) * | 2011-07-13 | 2015-08-06 | Gilead Sciences, Inc. | Thiophen-2-carboxylic acid derivatives useful as inhibitors of Flaviviridae viruses |
| WO2013016492A1 (en) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Thiophene compounds |
| WO2014055142A1 (en) | 2012-06-20 | 2014-04-10 | Cocrystal Discovery, Inc. | Inhibitors of hepatitis c virus polymerase |
| US8841340B2 (en) | 2012-08-17 | 2014-09-23 | Gilead Sciences, Inc. | Solid forms of an antiviral compound |
| US8927741B2 (en) | 2012-08-17 | 2015-01-06 | Gilead Sciences, Inc. | Synthesis of an antiviral compound |
| US8759544B2 (en) | 2012-08-17 | 2014-06-24 | Gilead Sciences, Inc. | Synthesis of an antiviral compound |
| AU2013305591B2 (en) | 2012-08-24 | 2017-04-13 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| WO2015070237A1 (en) | 2013-11-11 | 2015-05-14 | Board Of Regents Of The University Of Texas System | Neuroprotective chemicals and methods for identifying and using same |
| WO2015070234A2 (en) | 2013-11-11 | 2015-05-14 | Board Of Regents Of The University Of Texas System | Neuroprotective compounds and use thereof |
| TWI731854B (zh) | 2015-03-23 | 2021-07-01 | 美商共結晶製藥公司 | C型肝炎病毒聚合酶之抑制劑 |
| MX2020011912A (es) | 2018-05-09 | 2021-01-29 | Cocrystal Pharma Inc | Terapia de combinacion para el tratamiento del virus de la hepatitis c (vhc). |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995005170A1 (en) * | 1993-08-13 | 1995-02-23 | Warner-Lambert Company | Methods of inhibiting hiv and inhibiting the activation of hiv |
| US5734081A (en) * | 1994-08-05 | 1998-03-31 | Warner-Lambert Company | Arylthio compounds |
| KR20020060160A (ko) * | 1999-08-12 | 2002-07-16 | 파마시아 이탈리아 에스.피.에이. | 3(5)-아미노-피라졸 유도체, 이의 제조 방법 및항종양제로서의 이의 용도 |
| US20030096737A1 (en) * | 2001-04-19 | 2003-05-22 | Anita Diu-Hercend | Caspase inhibitors and uses thereof |
| US6887877B2 (en) * | 2001-06-11 | 2005-05-03 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of Flavivirus infections |
| CN101624391A (zh) * | 2001-06-11 | 2010-01-13 | 病毒化学医药公司 | 用作黄病毒感染抗病毒剂的噻吩衍生物 |
-
2003
- 2003-12-09 JP JP2004557712A patent/JP4926403B2/ja not_active Expired - Fee Related
- 2003-12-09 EP EP03767343A patent/EP1569929B9/en not_active Expired - Lifetime
- 2003-12-09 AU AU2003291885A patent/AU2003291885A1/en not_active Abandoned
- 2003-12-09 WO PCT/CA2003/001912 patent/WO2004052885A1/en not_active Ceased
- 2003-12-09 DK DK03767343.1T patent/DK1569929T3/da active
- 2003-12-09 MX MXPA05006196A patent/MXPA05006196A/es active IP Right Grant
- 2003-12-09 AT AT03767343T patent/ATE466856T1/de active
- 2003-12-09 CA CA2508990A patent/CA2508990C/en not_active Expired - Fee Related
- 2003-12-09 NZ NZ540799A patent/NZ540799A/en not_active IP Right Cessation
- 2003-12-09 BR BR0316771-2A patent/BR0316771A/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1569929B9 (en) | 2011-09-14 |
| NZ540799A (en) | 2008-09-26 |
| JP2006510636A (ja) | 2006-03-30 |
| JP4926403B2 (ja) | 2012-05-09 |
| BR0316771A (pt) | 2005-10-25 |
| EP1569929A1 (en) | 2005-09-07 |
| WO2004052885A1 (en) | 2004-06-24 |
| MXPA05006196A (es) | 2006-01-27 |
| ATE466856T1 (de) | 2010-05-15 |
| CA2508990A1 (en) | 2004-06-24 |
| EP1569929B1 (en) | 2010-05-05 |
| CA2508990C (en) | 2013-05-28 |
| DK1569929T3 (da) | 2010-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003291885A1 (en) | Compounds and methods for the treatment or prevention of flavivirus infections | |
| EA200400022A1 (ru) | Соединения и способы лечения или предупреждения инфекций flavivirus | |
| AU2002360592A1 (en) | Inhibitors of hepatitis c virus | |
| EP2546246A3 (en) | Compounds and methods for the treatment or prevention of flavivirus infections | |
| MY151199A (en) | Substituted diphenyl heterocycles useful for treating hcv infection | |
| NO20045247L (no) | Nukleosidderivater for behandling av hepatitt C-virusinfeksjon | |
| WO2004002940A8 (en) | Inhibitors of hcv ns5b polymerase | |
| PE20050204A1 (es) | Compuestos inhibidores de la hepatitis c | |
| NO20003233D0 (no) | 4-hydrokykinolin-3-karboksamider og hydraziner som antivirale midler | |
| GB0215293D0 (en) | Viral inhibitors | |
| GB0413087D0 (en) | Therapeutic compounds | |
| NZ510369A (en) | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection | |
| DE60214179D1 (de) | IMIDAZOi1,2-AöPYRIDIN-DERIVATE ZUR PROPHYLAXE UND BEHANDLUNG VON HERPES-INFEKTIONEN | |
| NO20065075L (no) | Ikke-nukleosidbaserte revers-transkriptase-inhibitorer. | |
| MXPA04006041A (es) | Antivirales de piridoquinoxalina. | |
| TW200508218A (en) | Inhibitors of papilloma virus | |
| SG162614A1 (en) | Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors | |
| IL165259A0 (en) | Compounds useful in the treatment of anthraxa and inhibiting lethal factor | |
| WO2004054513A3 (en) | Methods and compositions for treating and preventing ear infections | |
| WO2002072581A3 (en) | Pyrazolopyriadine derivatives | |
| WO2004108687A3 (en) | Nitrogen-containing heteroaryl derivatives for the treatment of hcv-infection | |
| SG146685A1 (en) | Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them | |
| AU4485101A (en) | Antiviral therapy | |
| MY141975A (en) | Pyridyl substituted heterocycles useful for treating or preventing hcv infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |